VBI Vaccines (NASDAQ: VBIV) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.


This table compares VBI Vaccines and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VBI Vaccines -4,463.06% -49.17% -37.55%
Soligenix -90.93% -112.81% -71.98%

Earnings & Valuation

This table compares VBI Vaccines and Soligenix’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VBI Vaccines $550,000.00 554.57 -$23.20 million N/A N/A
Soligenix $10.45 million 1.74 -$3.24 million ($1.04) -2.00

Soligenix has higher revenue and earnings than VBI Vaccines.

Volatility and Risk

VBI Vaccines has a beta of 3.73, meaning that its stock price is 273% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500.

Insider and Institutional Ownership

21.0% of VBI Vaccines shares are owned by institutional investors. Comparatively, 2.1% of Soligenix shares are owned by institutional investors. 54.5% of VBI Vaccines shares are owned by insiders. Comparatively, 5.0% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for VBI Vaccines and Soligenix, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VBI Vaccines 0 0 3 0 3.00
Soligenix 0 0 2 0 3.00

VBI Vaccines currently has a consensus price target of $10.50, suggesting a potential upside of 119.67%. Soligenix has a consensus price target of $5.25, suggesting a potential upside of 152.40%. Given Soligenix’s higher probable upside, analysts clearly believe Soligenix is more favorable than VBI Vaccines.


VBI Vaccines beats Soligenix on 7 of the 11 factors compared between the two stocks.

About VBI Vaccines

VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.